Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade.
Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, Winter C, Malkova N, Sun F, Jaworski J, Best A, Pao L, Hebert A, Levit M, Protopopov A, Pollard J, Bahjat K, Wiederschain D, Sharma S. Greco R, et al. Among authors: malkova n. Oncoimmunology. 2020 Sep 13;9(1):1811605. doi: 10.1080/2162402X.2020.1811605. Oncoimmunology. 2020. PMID: 33224628 Free PMC article.
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy.
Bernardo M, Tolstykh T, Zhang YA, Bangari DS, Cao H, Heyl KA, Lee JS, Malkova NV, Malley K, Marquez E, Pollard J, Qu H, Roberts E, Ryan S, Singh K, Sun F, Wang E, Bahjat K, Wiederschain D, Wagenaar TR. Bernardo M, et al. Oncoimmunology. 2021 Mar 16;10(1):1881268. doi: 10.1080/2162402X.2021.1881268. Oncoimmunology. 2021. PMID: 33796402 Free PMC article.
Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.
Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Bernardo M, Karikó K, Kreiter S, Kuhn AN, Levit M, Malkova N, Masciari S, Pollard J, Qu H, Ryan S, Selmi A, Schlereth J, Singh K, Sun F, Tillmann B, Tolstykh T, Weber W, Wicke L, Witzel S, Yu Q, Zhang YA, Zheng G, Lager J, Nabel GJ, Sahin U, Wiederschain D. Hotz C, et al. Among authors: malkova n. Sci Transl Med. 2021 Sep 8;13(610):eabc7804. doi: 10.1126/scitranslmed.abc7804. Epub 2021 Sep 8. Sci Transl Med. 2021. PMID: 34516826
[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. Boyko AN, et al. Among authors: malkova na. Zh Nevrol Psikhiatr Im S S Korsakova. 2024;124(4):86-96. doi: 10.17116/jnevro202412404186. Zh Nevrol Psikhiatr Im S S Korsakova. 2024. PMID: 38676683 Clinical Trial. Russian.
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.
Patel E, Malkova NV, Crowe D, Pederzoli-Ribeil M, Fantini D, Fanny M, Madala HR, Jenkins KA, Yerov O, Greene J, Guzman W, O'Toole C, Taylor J, O'Donnell RK, Johnson P, Lanter BB, Ames B, Chen J, Vu S, Wu HJ, Cantin S, McLaughlin M, Hsiao YS, Tomar DS, Rozenfeld R, Thiruneelakantapillai L, O'Hagan RC, Nicholson B, O'Neil J, Bialucha CU. Patel E, et al. Among authors: malkova nv. Mol Cancer Ther. 2024 Apr 2;23(4):421-435. doi: 10.1158/1535-7163.MCT-23-0336. Mol Cancer Ther. 2024. PMID: 38030380 Free PMC article.
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Bolsun DD, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. Boyko AN, et al. Among authors: malkova na. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(7. Vyp. 2):43-52. doi: 10.17116/jnevro202312307243. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37560833 Clinical Trial. Russian.
[POEMS-syndrome].
Arkhipov IE, Vergunova IY, Malkova NA, Korobko DS. Arkhipov IE, et al. Among authors: malkova na. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(7. Vyp. 2):15-21. doi: 10.17116/jnevro202312307215. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37560829 Russian.
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2].
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Shchur SG, Artemyeva AV, Bolsun DD, Zinkina-Orikhan AV, Linkova YN. Boyko AN, et al. Among authors: malkova na. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(4):37-47. doi: 10.17116/jnevro202312304137. Zh Nevrol Psikhiatr Im S S Korsakova. 2023. PMID: 37084363 Clinical Trial. Russian.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
5-Alkoxy-1-aryl-3-polyfluoroalkylpyrazoles with Antinociceptive Activity: Partial Agonists of TRPV1 Ion Channels.
Khudina OG, Burgart YV, Malkova NA, Shchegolkov EV, Krasnykh OP, Triandafilova GA, Malysheva KO, Solodnikov SY, Dubodel ES, Korolkova YV, Kozlov SA, Borisevich SS, Mozhaitsev ES, Saloutin VI. Khudina OG, et al. Among authors: malkova na. ChemMedChem. 2023 Jun 15;18(12):e202300063. doi: 10.1002/cmdc.202300063. Epub 2023 Apr 17. ChemMedChem. 2023. PMID: 37006199
123 results